Aptamer Group

Aptamer Group develops custom affinity tools through its proprietary Optimer™ platform to enable new approaches in research, diagnostics and therapeutics. The Company strives to deliver transformational solutions, that meet the needs of researchers and developers across the Life Sciences through the use of its proprietary Optimer platform. Optimer ligands are nucleic acid affinity ligands that can function as an antibody alternative. Despite many well-recognised problems with antibodies, the global antibody market is currently worth over $145Bn. Optimer ligands are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists. Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.